Search Results
The default setting for search results displays All Content. If you prefer to see recent content only, please adjust the date filter.
Filter your results:
Types
Topics
1300 Results Found
AHA Urges FTC to Withdraw Proposed Changes to Premerger Notification Rules
American Hospital Association opposes the Federal Trade Commission’s proposed amendments to the Hart-Scott-Rodino (HSR) form and instructions.
AHA Comment Letter on CMS' Home Health Prospective Payment System Proposed Rule for CY 2024
AHA's comment on the calendar year (CY) 2024 HH prospective payment system (PPS) proposed rule.
AHA Supports CMS' Proposed Changes on How Noncomprehensive Coverage Can Be Marketed and Sold
AHA comments on the CMS' proposed changes on how certain forms of noncomprehensive coverage, including short-term, limited-duration plans, can be marketed and sold.
AHA Letter of Support for the GOLD Card Act of 2023 (H.R. 4968
AHA voices support of the GOLD Card Act of 2023 (H.R. 4968).
AHA Comments on Energy and Commerce Committee's Drug Shortages Discussion Draft
AHA's comments on Energy and Commerce Committee Chair Rodgers’ drug shortages discussion draft.
AHA Responds to CMS' Episode Based Payment Model Request for Information
AHA provides feedback on CMS' Episode Based Payment request for information.
AHA Comments on IRS' Elective Payment of Applicable Credit Proposed Rule
The IRA, through the transferability provisions under Section 6418 and, in particular, the elective direct pay provisions of Section 6417, has provided new opportunities for the healthcare sector to engage in important clean energy initiatives.
AHA Letter of Support for the Drug Shortage Prevention Act of 2023
The Drug Shortage Prevention Act would require manufacturers to notify the Food and Drug Administration (FDA) of increased demand of covered drugs. The AHA believes the requirement that manufacturers notify the FDA of increased demand for critical drugs will be an integral tool for shoring up the supply chain.
AHA Letter of Support for the Rolling Active Pharmaceutical Ingredient and Drug, or RAPID, Reserve Act of 2023
Pharmaceutical shortages and supply chain failures can have a devastating impact on patients. The RAPID Reserve Act would establish a program to improve supply chain resiliency for critical generic drug products, ensuring adequate supply is available even in the event of a shortage.
AHA Letter of Support for the Pharmaceutical Supply Chain Risk Assessment Act of 2023
The Pharmaceutical Supply Chain Risk Assessment Act of 2023 would require a comprehensive risk assessment of the entire U.S. pharmaceutical supply chain. This overarching project will help provide critical information necessary to mitigate and prevent drug supply shortages.